Health

Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 07, 2026 19:07 ET  | Source: Cue Biopharma, Inc. BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.…

4 weeks ago

Novi GLP-1 Weight Loss Claims Evaluated: Trusted Semaglutide & Tirzepatide Prescription Medication Treatment Options with Dedicated Doctors

Sheridan, WY, May 07, 2026 (GLOBE NEWSWIRE) -- Compounded medications are not FDA-approved finished drug products. Novi connects eligible adults…

4 weeks ago

SteelPower Male Enhancement Ingredient Research Gains Attention Amongst Men for Powerful Performance Support

Aurora, CO, May 06, 2026 (GLOBE NEWSWIRE) -- These statements have not been evaluated by the Food and Drug Administration.…

4 weeks ago

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an…

4 weeks ago

InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in China

BEIJING, May 06, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the…

4 weeks ago

Immutrin appoints leading cardiovascular drug development expert Dr. Robert Blaustein as Chief Medical Officer and establishes US subsidiary

Former Edgewise and Merck leader brings more than 15 years’ experience to guide Immutrin’s clinical strategy as the Company advances…

4 weeks ago

Avactapresents new comparisons of pre|CISIONpayload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026

May 06, 2026 02:00 ET  | Source: Avacta Group PLC LONDON and PHILADELPHIA, May 06, 2026 (GLOBE NEWSWIRE) -- Avacta…

4 weeks ago

Novo Nordisk’s adjusted operating profit reached DKK 32,858 million in Q1 2026

Bagsværd, Denmark, 6 May 2026 - Financial report for the period 1 January 2026 to 31 March 2026    …

4 weeks ago

uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates

~ Advancing FDA interactions on AMT-130 for Huntington’s disease; Type B meeting scheduled for the second quarter of 2026 ~…

1 month ago

Sotera Health Delivers Strong First-Quarter 2026 Results and Reaffirms 2026 Outlook

Q1 2026 net revenues increased 10.0%, or 6.5% on a constant currency basis, compared to Q1 2025Q1 2026 net income…

1 month ago